Clinical trial
ATN-161 in Advanced Renal Cell Cancer
NCT00131651 · Attenuon, Industry · Terminated
Key facts
| NCT number | NCT00131651 |
|---|---|
| Title | ATN-161 in Advanced Renal Cell Cancer |
| Official title | A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer |
| Lead sponsor | Attenuon, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | ATN-161 |
| Enrollment | 36 |
| Start date | Aug 1, 2005 |
| First posted | Aug 19, 2005 |
| Last update posted | Dec 6, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: